Abstract
This study was designed to describe the safety profile of the single dose live attenuated Japanese encephalitis vaccine (LJEV) SA-14-14-2 given at the age of 9 months in the National Immunisation programme of Sri Lanka. cohort event monitoring (CEM) was conducted in the Jaffna district during November 2012 to January 2015. A representative sample of 3041 infants who received the LJEV at the age of 9 months was followed up actively over telephone interviews on days 1, 3, 14, 30 and 45 for adverse events (AE). Parents were encouraged to self-report in between these interviews. When an AE is notified, further clinical information was obtained through in-depth interviews and home/hospital visits to determine as an adverse event following immunisation (AEFI). Investigators independently reviewed each AEFI for consistent causal association with LJEV according to WHO causality assessment. Of the 2878 (94%) infants who completed the follow up of 14 days, 911 (32%) experienced 1423 AEFIs. Of them, 376 (26%) were identified as AEFI with consistent causal association to LJEV (AEFIc). Irritability (53/ 1000 doses administered) and fever ≥100.4° F (46/1000 doses administered) accounted for 41% and 35% of AEFIcrespectively. Majority of AEFI (940) were identified as inconsistent as there were alternate causes. Nineteen AEFIc in 14 infants were classified as serious since they led to hospitalisation. Of the 2392 (79%) infants who completed 45 days follow up, 1022 experienced 1804 AEFI during 15-45 days. Only 20 were identified as AEFIc. There were no reported fatal or life threatening AEs. LJEV administered to infants at 9 months was devoid of any significant safety concerns as most of the AEFIs were non-serious and resolved completely. CEM is a useful method for AEFI surveillance.
Highlights
Serious nature of the Japanese encephalitis (30% case fatality rate, 30-50% residual neurological deficits), absence of effective treatment, and the disease burden were the decisive factors for incorporating mouse brain derived inactivated Japanese encephalitis (MBDJE) vaccine in the National Immunisation Programme (NIP) of Sri Lanka in 1988 [1, 2]
LJEV administered to infants at 9 months was devoid of any significant safety concerns as most of the adverse event following immunisation (AEFI) were non-serious and resolved completely
cohort event monitoring (CEM) is a useful method for AEFI surveillance
Summary
Serious nature of the Japanese encephalitis (30% case fatality rate, 30-50% residual neurological deficits), absence of effective treatment, and the disease burden were the decisive factors for incorporating mouse brain derived inactivated Japanese encephalitis (MBDJE) vaccine in the National Immunisation Programme (NIP) of Sri Lanka in 1988 [1, 2]. The MBDJE vaccine was replaced by the single dose live attenuated Japanese encephalitis (SA-14-14-2) vaccine (LJEV) in 2009 [2, 3]. Effectiveness of an immunisation programme mainly depends on the efficacy and safety of the vaccine and its expected high coverage of target population. The MBDJE vaccine could not be sustained in the programme because of its safety, cost and feasibility constraints. Cost and feasibility constraints were mainly related to its four doses schedule (primary – day 0, day 30, boosters 1 and 4 years apart).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.